Premium
Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery
Author(s) -
Large Danielle E.,
Soucy Jonathan R.,
Hebert Jacob,
Auguste Debra T.
Publication year - 2019
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.201800091
Subject(s) - drug delivery , drug , in vivo , targeted drug delivery , pharmacology , receptor , biodistribution , gene delivery , medicine , biology , genetic enhancement , nanotechnology , gene , materials science , microbiology and biotechnology , biochemistry
Receptor‐mediated drug delivery presents an opportunity to enhance therapeutic efficiency by accumulating drug within the tissue of interest and reducing undesired, off‐target effects. In cancer, receptor overexpression is a platform for binding and inhibiting pathways that shape biodistribution, toxicity, cell binding and uptake, and therapeutic function. This review will identify tumor‐targeted drug delivery vehicles and receptors that show promise for clinical translation based on quantitative in vitro and in vivo data. The authors describe the rationale to engineer a targeted drug delivery vehicle based on the ligand, chemical conjugation method, and type of drug delivery vehicle. Recent advances in multivalent targeting and ligand organization on tumor accumulation are discussed. Revolutionizing receptor‐mediated drug delivery may be leveraged in the therapeutic delivery of chemotherapy, gene editing tools, and epigenetic drugs.